Identification | |||||||||
---|---|---|---|---|---|---|---|---|---|
Name | Sevelamer | ||||||||
Accession Number | DB00658 (APRD01226) | ||||||||
Type | small molecule | ||||||||
Description | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel. | ||||||||
Structure |
|
||||||||
Categories (*) | |||||||||
Molecular Weight | 149.619 | ||||||||
Groups | approved | ||||||||
Monoisotopic Weight | 149.060741718 | ||||||||
Pharmacology | |||||||||
Indication | For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis. | ||||||||
Mechanism of action | Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels. | ||||||||
Absorption | Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease. | ||||||||
Protein binding | Not Available | ||||||||
Biotransformation | Not Available | ||||||||
Route of elimination | Not Available | ||||||||
Toxicity | Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low. | ||||||||
Affected organisms |
|
||||||||
Interactions | |||||||||
Drug Interactions |
|
||||||||
Food Interactions | Not Available |
Phosphate | |
---|---|
Name | Phosphate |
Gene Name | Not Available |
Pharmacological action | yes |
Actions | binder |
References |
|
DTHybrid score | Not Available |
Id | Partner name | Gene Name | Score |
---|